4basebio PLC (LON:4BB – Get Free Report) insider Heikki Lanckriet acquired 2,400 shares of the business’s stock in a transaction dated Wednesday, April 2nd. The shares were bought at an average cost of GBX 1,205 ($15.54) per share, with a total value of £28,920 ($37,306.50).
4basebio Stock Up 1.7 %
Shares of 4BB stock opened at GBX 1,205 ($15.54) on Friday. 4basebio PLC has a one year low of GBX 901 ($11.62) and a one year high of GBX 1,820 ($23.48). The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52. The stock has a fifty day moving average price of GBX 1,142.07 and a 200 day moving average price of GBX 1,232.05. The stock has a market cap of £154.36 million, a P/E ratio of -1,544.87 and a beta of 1.09.
Analyst Ratings Changes
Separately, Royal Bank of Canada reiterated an “outperform” rating and issued a GBX 1,600 ($20.64) price objective on shares of 4basebio in a research report on Thursday, March 13th.
About 4basebio
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.
Featured Stories
- Five stocks we like better than 4basebio
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- Should You Invest in Penny Stocks?
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
